Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This is as the company has delivered steady growth in revenue ...

The stock of Vertex Pharmaceuticals Incorporated VRTX has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss ...

The increasing adoption of e-invoicing globally and the ongoing enterprise resource planning (ERP) migration super cycle present multi-year growth opportunities for Vertex. As companies shift to cloud ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. However, the big drugmaker had plenty of good news in its Q1 update, too.

This non-opioid pain drug targets a multibillion-dollar market. Vertex also has multiple other catalysts on the way in 2025 and over the next few years. It usually doesn't matter if you buy a given ...

Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.

Vertex has delivered earnings growth over the past decade thanks to its leadership in cystic fibrosis treatment. In recent years, the company has launched products in other treatment areas too. 10 ...